-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Enliven Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2019 to Q3 2024.
- Enliven Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$27.1M, a 11.6% decline year-over-year.
- Enliven Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$100M, a 41.5% decline year-over-year.
- Enliven Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$83.5M, a 115% decline from 2022.
- Enliven Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$38.8M, a 56.7% decline from 2021.
- Enliven Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$24.8M, a 40.6% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)